Tumor Immunotherapy, Bispecific Antibodies, CAR T

OriCell Therapeutics is focused on developing advanced immunotherapies, particularly in the field of oncology, utilizing proprietary technologies to enhance the efficacy of cell therapies. Their OriAb platform boasts one of the largest antibody libraries, which is instrumental in screening and optimizing antibodies for CAR-T programs. This platform is complemented by the OriCAR technology, which generates CAR constructs designed to improve T cell infiltration, maintain a high ratio of memory T cells, and exhibit resistance to exhaustion within the tumor microenvironment. These innovations aim to enhance anti-tumor activities, making OriCell's therapies more effective against various malignancies.

The company has made significant strides in clinical development, particularly with its CAR-T therapies targeting specific antigens such as GPRC5D and GPC3. OriCAR-017, a GPRC5D-targeting autologous CAR-T therapy, has received multiple regulatory approvals, including IND clearance from both the FDA and China's NMPA. OriCell's commitment to addressing unmet medical needs is further demonstrated through its ongoing clinical trials and collaborations with leading experts in the field, positioning the company as a frontrunner in the development of innovative treatments for hematological cancers and solid tumors.

China

Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

OriCell Therapeutics

Company Details